Preparation midbody for Ezetimibe and preparation method of preparation midbody
A technology for ezetimibe and intermediates, which is applied in the field of preparation of lipid-lowering drug-ezetimibe and its preparation, which can solve the problems of low total yield, limited industrial production, and easy ring opening
Patent Information
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Publication Date
- 2014-12-24
Smart Images
Figure 1 Figure 2 Figure 3
Abstract
Description
technical field
[0001] The invention belongs to the field of medicinal chemistry, and in particular relates to a preparation intermediate of a lipid-lowering drug-ezetimibe and a preparation method thereof. Background technique
[0002] Ezetimibe, chemical name (3R,4S)-1-(4-fluorophenyl)-3-[(3S)-3-(4-fluorophenyl)-3-hydroxypropyl] -4-(4-hydroxyphenyl)-2-azetidinone is a blood lipid-lowering drug and belongs to selective cholesterol absorption inhibitors. The drug binds to the membrane protein on the small intestinal brush border membrane vesicles, inhibits the body's absorption of cholesterol, thereby lowering the cholesterol level and lowering blood lipids.
[0003]
[0004] Structurally, ezetimibe has three chiral centers, which are the 3 and 4 positions of azetidinone and the 3'-position chiral carbon atom connected to the hydroxyl group on the side chain connected to the 3 position. The synthesis of ezetimibe focuses on the ability to form these three chiral centers...
Examples
Embodiment 1
[0032] Embodiment 1. The synthesis of compound IV
[0033]
[0034] Add 5-(4-fluorophenyl)-5-oxopentanoic acid (20g, 95mmol), (S)-4-(2-chlorophenyl)-2-oxazolone (19g, 96mmol) into a 500ml three-necked flask ), N,N'-dicyclohexylcarbodiimide (19.8g, 96mmol) and dichloromethane 200ml, stirred at room temperature for 12 hours. Filter and wash the organic layer with 3% dilute hydrochloric acid (80ml). The organic layer was concentrated and the product was crystallized from isopropanol (150ml), filtered and dried. 31 g of the product was obtained with a yield of 83.7%. 1 H NMR (400MHz, CDCl 3 ):δ2.05(m,2H),2.94(m,2H),3.05(m,2H),4.26(m,1H),4.67(t,1H),5.42(m,1H),7.08(m, 2H),7.30(m,4H),7.89(m,2H).
Embodiment 2
[0035] Embodiment 2. Synthesis of Compound II
[0036]
[0037]Dry dichloromethane (20ml) and borane dimethyl sulfide (2.82ml, 28.2mmol) were added to a 250ml three-necked flask, and the mixture was cooled to -5-0°C. Add (R)-MeCBS toluene solution (1.4ml, 1.4mmol, 5%mol), and stir at 0°C for 15 minutes, slowly add compound IV (10g, 25.7mmol) in dichloromethane within 3-4 hours (30ml) solution, the reaction temperature is controlled at -5~0 degree. Stirring was continued for 1-2 hours. The reaction was quenched by the slow addition of methanol (4ml) while maintaining the temperature below 0°C. 5% hydrogen peroxide (20ml) was added followed by 4N sulfuric acid (1.5ml). The mixture was stirred for 15 minutes, the organic layer was separated and washed with 2N sulfuric acid (20ml), 5% sodium bisulfite (50ml) and 10% sodium chloride (50ml). The organic layer was concentrated to low volume until the water content was less than 0.05%. The product was used directly in the next...
Embodiment 3
[0038] Example 3. Synthesis of compound I (PG trimethylsilyl)
[0039]
[0040] A dichloromethane solution of compound II (10 g equivalent of compound 6, 25 mmol) and compound III (12.05 g) obtained from the previous step were added to a 500 ml three-necked flask, and the total volume of the reaction mixture was adjusted to 150 ml using anhydrous dichloromethane. The mixture was cooled to 1 H NMR (400MHz, CDCl3): δ-0.07(s,9H),0.28(s,9H),1.41(m,1H),1.55(m,3H),4.21(m,1H),4.29(m,1H ),4.46(m,2H),4.47(m,1H),5.43(m,1H),6.43(m,2H),6.77(m,4H),6.98(m,2H),7.06(m,2H) ,7.18(m,7H).